Detalles de la búsqueda
1.
A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
Drug Metab Dispos
; 45(4): 361-374, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28122787
2.
Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers.
Br J Clin Pharmacol
; 82(4): 1022-9, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27277189
3.
Exposure-QT analysis for sonidegib (LDE225), an oral inhibitor of the hedgehog signaling pathway, for measures of the QT prolongation potential in healthy subjects and in patients with advanced solid tumors.
Eur J Clin Pharmacol
; 72(12): 1427-1432, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27663457
4.
Population Pharmacokinetics of Subcutaneous Pasireotide in Healthy Volunteers and Cushing's Disease Patients.
Clin Pharmacokinet
; 57(7): 855-866, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29032486
5.
Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.
Clin Pharmacokinet
; 57(3): 345-354, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28577129
6.
Exposure-Response Analysis of Sonidegib (LDE225), an Oral Inhibitor of the Hedgehog Signaling Pathway, for Effectiveness and Safety in Patients With Advanced Solid Tumors.
J Clin Pharmacol
; 56(11): 1406-1415, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27095306
7.
Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 77(4): 745-55, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26898300
Resultados
1 -
7
de 7
1
Próxima >
>>